Q1 2027 Blue Jet Healthcare Ltd Earnings Call Transcript
Key Points
- Revenue from operations grew 25% sequentially to INR293 crore, with EBITDA up to 33.5% from 30.4%, reflecting strong operating leverage.
- PI/API segment rebounded as customer destocking normalized, with strong order visibility expected to sustain FY2027 performance.
- Unit III backward integration project is ahead of schedule, with commercial contribution expected in H2 FY2027, enhancing vertical integration in contrast media.
- Vizag project secured ~100 acres and received key approvals, with Phase 1 capex of ~INR1,000 crore planned against identified customer opportunities.
- Hyderabad R&D center is on track to become operational this month, strengthening capabilities in peptides, biocatalysis, and flow synthesis.
- Pipeline progress: three contrast media launches expected in FY2027, pilot for new high-intensity sweetener, and four high-conviction NCE programs in chronic therapy advancing.
- QIP completion strengthens balance sheet, providing financial flexibility for strategic expansion.
- Sustainability achievements: ~70% renewable energy usage and EcoVadis Silver Medal, enhancing prequalification with customers.
- Contrast media revenue declined ~40% sequentially due to transit delays and higher goods in transit (INR30 crore), impacting Q1 sales recognition.
- Gross margin fell 3% sequentially to 53% due to raw material price increases and product mix, with uncertain pricing trends ahead.
- Raw material costs have risen significantly post-geopolitical situation, with pass-through to customers expected only with a lag.
- Profit after tax margin declined 0.7% sequentially to 26.7%, partly due to lower other income from reduced forex gains.
- Capex of ~INR250 crore in FY2027 and INR1,000 crore over three years will pressure asset turns, which are expected to normalize to industry standards.
- New product contributions (e.g., iodinated contrast media, lateral entries) remain uncertain, with commercialization expected only by end Q2 or beginning Q3.
- High dependence on a single PI/API molecule (bempedoic acid) persists, though diversification is planned.
- Geopolitical situation creates uncertainty in raw material pricing and logistics, impacting near-term performance.
Ladies and gentlemen, good day and welcome to the Blue Jet Healthcare Limited Q1 FY2027 Earnings Conference Call.
(Operator Instructionss)
Please note that this conference is being recorded.
I now hand the conference over to Advait from EY. Thank you. Over to you, sir.
Thank you, Shruti.
Good evening, and warm welcome, everyone, to Q1 FY2027 Earnings Call of
Blue Jet Healthcare Limited. Please note the investor presentation and the financial results are available on the company's website and the stock exchanges. Also anything said on this call, which reflects our outlook for the future or which should be construed as a forward-looking statement must be reviewed in conjunction with the risks that the company face
The conference call is being recorded under transfer along with audio of the team will be made available on the company website, as well as on the Exchanges. Please also note that the audio of the conference call is the corporate material
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
